Gene Polymorphisms and Serum Levels of Pro- and Anti-Inflammatory Markers in Dengue Viral Infections

2016 ◽  
Vol 29 (7) ◽  
pp. 379-388 ◽  
Author(s):  
Rosimar Neris Martins Feitosa ◽  
Antonio Carlos Rosário Vallinoto ◽  
Pedro Fernando da Costa Vasconcelos ◽  
Raimunda do Socorro da Silva Azevedo ◽  
Vânia Nakauth Azevedo ◽  
...  
Keyword(s):  
Inflammatory Markers ◽  
Gene Polymorphisms ◽  
Viral Infections ◽  
Serum Levels ◽  
Anti Inflammatory

scholarly journals Ferritin and LDH as Predictors of Mortality in COVID-19 Infection, Bosnia and Herzegovina Single-center Study

2021 ◽  
Author(s):  
Vahid Jusufovic ◽  
Sekib Umihanic ◽  
Ervin Alibegovic ◽  
Dilista Piljic ◽  
Amer Mujkanovic ◽  
...  
Keyword(s):  
Treatment Planning ◽  
Serum Ferritin ◽  
Inflammatory Markers ◽  
Statistical Difference ◽  
Viral Infections ◽  
Serum Levels ◽  
Clinical Settings ◽  
Lethal Outcome ◽  
Significant Statistical Difference ◽  
Single Center Study

Abstract Background Since the beginning of the COVID-19 pandemic, several inflammatory markers have been investigated as possible predictors of survival. Ferritin and from recently LDH have emerged as a possible marker that could serve to this purpose, with different cut-off levels than standard. Furthermore, serum elevations of these markers were reported in other viral infections such as dengue fever; while it has not been reported in MERS and SARS outbreaks and possibly making a biochemical distinction between COVID-19 and other similar diseases. The aim of this research was to establish independent admission levels of ferritin and LDH that predict lethal outcome more accurately. Methods In this prospective cohort study all the patients were hospitalized at UKC, B&H (n=137), between 28th of March and 1st of August 2020. The criteria for hospitalization was based on MEWS score, and all the inflammatory markers were evaluated in the first 72 hours of admission. Cut-off values of serum ferritin levels were set at 1500 ng/mL and LDH 350 U/L. Results Patients with serum ferritin levels >1500 ng/mL had 7.304 OR (CI95% 1.956-27.277; p=0.003) higher for lethal outcome than the group with <1500 ng/mL. Also, patients with levels of LDH >350 U/I had 5.560 (CI95% 2.480-12.468; p<0.001) higher OR of lethal outcome than patients with LDH <350 U/L. With the significant statistical difference between group means for both ferritin and LDH (p<0.001).Discussion Serum levels of ferritin >1500 ng/ml and LDH >350 U/L increase OR of lethal outcome. The levels of these inflammatory markers indicate the degree of inflammatory response and severity of the disaese as well as the possible outcome of the disease. Together these two markers could be used as predictors in clinical settings and treatment planning of patients with COVID-19.Conclusion: Together these two markers could be used as predictors in clinical settings and treatment planning of patients with COVID-19.

Fitness is associated with lower inflammatory markers in obesity: the FATCOR study

2020 ◽  
Vol 41 (Supplement_2) ◽  
Author(s):  
H Midtboe ◽  
A Ulvik ◽  
K Meyer ◽  
P.M Ueland ◽  
H Halland ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Inflammatory Markers ◽  
Cardiopulmonary Exercise Testing ◽  
Serum Levels ◽  
Peak Oxygen Uptake ◽  
Low Grade ◽  
Funding Source ◽  
Amyloid A ◽  
Anti Inflammatory ◽  
Overweight Subjects

Abstract Background Obesity is associated with chronic low-grade inflammation, but exercise has anti-inflammatory properties. It is unknown whether the anti-inflammatory effects of fitness may influence the obesity-associated inflammation. Purpose To assess levels of inflammatory markers in fit vs. unfit overweight and obese subjects without known cardiovascular disease. Methods Peak oxygen uptake (VO2max) was measured by treadmill cardiopulmonary exercise testing in 566 subjects (mean age 48±9 years, 60% women) with body mass index &gt;27.0 kg/m2 in the FAT associated CardiOvasculaR dysfunction (FATCOR) study. Fitness was defined from age- and sex adjusted reference levels of VO2max. Serum levels of C-reactive protein (CRP), serum amyloid A (SAA) and calprotectin were assessed by Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight (MALDI-TOF) mass spectrometry and log transformed before inclusion in analyses. Results Fit subjects (n=147) were older and had less metabolic syndrome, obesity and hypertension compared to unfit subjects (n=419) (all p&lt;0.05). Serum levels of CRP and SAA were lower in fit subjects vs. unfit (p&lt;0.01), while serum calprotectin showed no difference (p=0.06). In multivariable logistic regression analyses, lower CRP (odds ratio [OR] 0.73, 95% confidence interval [CI] 0.61–0.87, p&lt;0.001) and SAA (OR 0.61, 95% CI 0.40–0.93, p=0.02) remained associated with being fit after adjusting for age, sex, obesity, metabolic syndrome and hypertension. When looking at obese (n=357, fit n=53) and overweight subjects (n=209, fit n=94) separately, lower CRP (OR 0.60, 95% CI 0.46–0.78, p&lt;0.001) and SAA (OR 0.44, 95% CI 0.24–0.83, p=0.01) remained associated with being fit in obese, but not in overweight subjects after adjustment for age, sex and metabolic syndrome. Conclusion Fitness was associated with lower circulatory inflammatory markers in obesity independent of cardiometabolic risk factors. Our results suggest that fitness may promote cardiovascular benefit through the anti-inflammatory properties of exercise also in obesity. Funding Acknowledgement Type of funding source: Public grant(s) – National budget only. Main funding source(s): The Western Norway Regional Health Authority

scholarly journals Pentoxifylline, a drug with antiviral, anti-inflammatory and bronchodilatory effects may be a possible drug candidate for SARS-CoV-2

2020 ◽  
Author(s):  
Morteza Ghasemnejad-Berenji ◽  
Sarvin Pashapour ◽  
Sonia Sadeghpour
Keyword(s):  
Viral Infections ◽  
Immune Cell ◽  
Low Cost ◽  
Elevated Serum ◽  
Phosphodiesterase Inhibitor ◽  
Adenosine Monophosphate ◽  
Serum Levels ◽  
Drug Candidate ◽  
Anti Inflammatory

In December 2019, a new coronavirus, named SARS-CoV-2, has emerged from China causing pneumonia outbreaks first in the Wuhan region and have now spread worldwide but there are still no “specific drug” available. In the difficulty where new synthesized drug cannot be applied immediately to patients, “conventional drug in new use” becomes a feasible solution. Chloroquine, remdesivir, favipiravi, lopinavir, ribavirin or ritonavir have shown efficacy to inhibit coronavirus in vitro. Pentoxifylline, a drug with anti-inflammatory, immunomodulatory and bronchodilatory effects, previously showed efficacy to inhibit various viral infections. Immunological studies have shown that most patients with severe COVID-19 exhibit substantially elevated serum levels of pro-inflammatory cytokines. Pentoxifylline is a phosphodiesterase inhibitor that increases cyclic adenosine monophosphate levels, which in turn activate protein kinase, leading to a reduction in the synthesis of proinflammatory cytokines and immune cell migration. Here we propose pentoxifylline, a drug with low cost and toxicity, as a possible treatment for COVID-19 in basis of its interesting properties.

scholarly journals The retrospective study of perioperative application of dexamethasone and furosemide for postoperative anti-inflammation in patients undergoing percutaneous nephrolithotomy

2021 ◽  
Author(s):  
Taiguo Qi ◽  
Xia Qi ◽  
Xiude Chen ◽  
Xunbo Jin
Keyword(s):  
Clinical Outcome ◽  
Hospital Stay ◽  
Percutaneous Nephrolithotomy ◽  
Inflammatory Markers ◽  
Serum Levels ◽  
Postoperative Hospital Stay ◽  
Lower Serum ◽  
Combined Application ◽  
Furosemide Administration ◽  
Anti Inflammation

Abstract Objectives To investigate whether the perioperatively combined application of dexamethasone and furosemide could alleviate the inflammation in patients undergoing percutaneous nephrolithotomy (PCNL). Patients and methods 147 patients undergoing PCNL between November 2018 and October 2019 were enrolled in the study. 77 patients accepted a single dose of dexamethasone and furosemide administration (EXP group, n = 77), and 70 patients did not (CON group, n = 70). Demographic and perioperative data, inflammatory markers including interleukin-6 (IL-6) and procalcitonin (PCT), and clinical outcomes were compared between the two groups. Results Compared with the CON group, the incidence rate of urosepsis of the EXP group were significantly lower (11.69% vs. 24.29%, p = 0.046). 3 patients developed severe urosepsis in the EXP group, while 5 patients developed severe urosepsis in the CON group. Compared with those in the CON group, the patients with postoperative urosepsis in the EXP group showed lower serum levels of IL-6 at postoperative hour two (p = 0.045) and at postoperative day one (p = 0.031) and lower serum levels of PCT at postoperative day one (p = 0.015). There was a better clinical outcome of a shorter postoperative hospital stay (p = 0.015) in patients with postoperative urosepsis in the EXP group than in those in the CON group. Conclusion The perioperatively combined application of dexamethasone and furosemide was beneficial for alleviating postoperative inflammatory reaction and caused a better clinical outcome of a shorter postoperative hospital stay.

scholarly journals Dipterocarpus tuberculatus Roxb. Ethanol Extract Has Anti-Inflammatory and Hepatoprotective Effects In Vitro and In Vivo by Targeting the IRAK1/AP-1 Pathway

Molecules ◽  
2021 ◽  
Vol 26 (9) ◽  
pp. 2529
Author(s):  
Haeyeop Kim ◽  
Woo Seok Yang ◽  
Khin Myo Htwe ◽  
Mi-Nam Lee ◽  
Young-Dong Kim ◽  
...  
Keyword(s):  
Ethanol Extract ◽  
Serum Levels ◽  
Hepatoprotective Activity ◽  
Tnf Α ◽  
Anti Inflammatory ◽  
Related Proteins ◽  
Pro Inflammatory Cytokines ◽  
Inflammatory Effect

Dipterocarpus tuberculatus Roxb. has been used traditionally as a remedy for many diseases, especially inflammation. Therefore, we analyzed and explored the mechanism of the anti-inflammatory effect of a Dipterocarpus tuberculatus Roxb. ethanol extract (Dt-EE). Dt-EE clearly and dose-dependently inhibited the expression of pro-inflammatory cytokines such as IL-6, TNF-α, and IL-1β in lipopolysaccharide (LPS)-treated RAW264.7 cells. Also, Dt-EE suppressed the activation of the MyD88/TRIF-mediated AP-1 pathway and the AP-1 pathway related proteins JNK2, MKK4/7, and TAK1, which occurred as a result of inhibiting the kinase activity of IRAK1 and IRAK4, the most upstream factors of the AP-1 pathway. Finally, Dt-EE displayed hepatoprotective activity in a mouse model of hepatitis induced with LPS/D-galactosamine (D-GalN) through decreasing the serum levels of alanine aminotransferase and suppressing the activation of JNK and IRAK1. Therefore, our results strongly suggest that Dt-EE could be a candidate anti-inflammatory herbal medicine with IRAK1/AP-1 inhibitory and hepatoprotective properties.

scholarly journals Statement of Retraction: The Association of Interleukin-16 Gene Polymorphisms with IL-16 Serum Levels and Risk of Multiple Sclerosis

2021 ◽  
pp. 1-1
Author(s):  
Mehrdad Farrokhi ◽  
Aria Masoudifar ◽  
Ali Derakhshan ◽  
Samira Saadatmand ◽  
Hojjat Rouhi-Boroujeni ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Gene Polymorphisms ◽  
Serum Levels

scholarly journals Molecular and Biochemical Pathways of Catalpol in Alleviating Diabetes Mellitus and Its Complications

Biomolecules ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 323
Author(s):  
Subrat Kumar Bhattamisra ◽  
Hui Min Koh ◽  
Shin Yean Lim ◽  
Hira Choudhury ◽  
Manisha Pandey
Keyword(s):  
Diabetes Mellitus ◽  
Diabetic Complications ◽  
Inflammatory Markers ◽  
Phosphoenolpyruvate Carboxykinase ◽  
Neuroprotective Effect ◽  
Antioxidant Properties ◽  
Beneficial Effects ◽  
Ppar Γ ◽  
High Glucose Condition ◽  
Anti Inflammatory

Catalpol isolated from Rehmannia glutinosa is a potent antioxidant and investigated against many disorders. This review appraises the key molecular pathways of catalpol against diabetes mellitus and its complications. Multiple search engines including Google Scholar, PubMed, and Science Direct were used to retrieve publications containing the keywords “Catalpol”, “Type 1 diabetes mellitus”, “Type 2 diabetes mellitus”, and “diabetic complications”. Catalpol promotes IRS-1/PI3K/AKT/GLUT2 activity and suppresses Phosphoenolpyruvate carboxykinase (PEPCK) and Glucose 6-phosphatase (G6Pase) expression in the liver. Catalpol induces myogenesis by increasing MyoD/MyoG/MHC expression and improves mitochondria function through the AMPK/PGC-1α/PPAR-γ and TFAM signaling in skeletal muscles. Catalpol downregulates the pro-inflammatory markers and upregulates the anti-inflammatory markers in adipose tissues. Catalpol exerts antioxidant properties through increasing superoxide dismutase (sod), catalase (cat), and glutathione peroxidase (gsh-px) activity in the pancreas and liver. Catalpol has been shown to have anti-oxidative, anti-inflammatory, anti-apoptosis, and anti-fibrosis properties that in turn bring beneficial effects in diabetic complications. Its nephroprotective effect is related to the modulation of the AGE/RAGE/NF-κB and TGF-β/smad2/3 pathways. Catalpol produces a neuroprotective effect by increasing the expression of protein Kinase-C (PKC) and Cav-1. Furthermore, catalpol exhibits a cardioprotective effect through the apelin/APJ and ROS/NF-κB/Neat1 pathway. Catalpol stimulates proliferation and differentiation of osteoblast cells in high glucose condition. Lastly, catalpol shows its potential in preventing neurodegeneration in the retina with NF-κB downregulation. Overall, catalpol exhibits numerous beneficial effects on diabetes mellitus and diabetic complications.

scholarly journals Role of Inflammatory Cytokines in COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions, Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm

Vaccines ◽  
2021 ◽  
Vol 9 (5) ◽  
pp. 436
Author(s):  
Ali A. Rabaan ◽  
Shamsah H. Al-Ahmed ◽  
Javed Muhammad ◽  
Amjad Khan ◽  
Anupam A Sule ◽  
...  
Keyword(s):  
Inflammatory Cytokines ◽  
Inflammatory Markers ◽  
Therapeutic Drug ◽  
Molecular Pathways ◽  
Cytokine Storm ◽  
Immunomodulatory Drugs ◽  
Alveolar Cells ◽  
Systemic Complications ◽  
Anti Inflammatory ◽  
Pro Inflammatory Cytokines

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a severe pandemic of the current century. The vicious tentacles of the disease have been disseminated worldwide with unknown complications and repercussions. Advanced COVID-19 syndrome is characterized by the uncontrolled and elevated release of pro-inflammatory cytokines and suppressed immunity, leading to the cytokine storm. The uncontrolled and dysregulated secretion of inflammatory and pro-inflammatory cytokines is positively associated with the severity of the viral infection and mortality rate. The secretion of various pro-inflammatory cytokines such as TNF-α, IL-1, and IL-6 leads to a hyperinflammatory response by recruiting macrophages, T and B cells in the lung alveolar cells. Moreover, it has been hypothesized that immune cells such as macrophages recruit inflammatory monocytes in the alveolar cells and allow the production of large amounts of cytokines in the alveoli, leading to a hyperinflammatory response in severely ill patients with COVID-19. This cascade of events may lead to multiple organ failure, acute respiratory distress, or pneumonia. Although the disease has a higher survival rate than other chronic diseases, the incidence of complications in the geriatric population are considerably high, with more systemic complications. This review sheds light on the pivotal roles played by various inflammatory markers in COVID-19-related complications. Different molecular pathways, such as the activation of JAK and JAK/STAT signaling are crucial in the progression of cytokine storm; hence, various mechanisms, immunological pathways, and functions of cytokines and other inflammatory markers have been discussed. A thorough understanding of cytokines’ molecular pathways and their activation procedures will add more insight into understanding immunopathology and designing appropriate drugs, therapies, and control measures to counter COVID-19. Recently, anti-inflammatory drugs and several antiviral drugs have been reported as effective therapeutic drug candidates to control hypercytokinemia or cytokine storm. Hence, the present review also discussed prospective anti-inflammatory and relevant immunomodulatory drugs currently in various trial phases and their possible implications.

Sign in / Sign up

Export Citation Format

Share Document